Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC.

(IMMU)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
87.56(c) 87.61(c) 87.72(c) 87.82(c) 87.86 Last
4 393 145 4 240 329 2 937 263 5 346 726 15 302 921 Volume
+0.08% +0.06% +0.13% +0.11% +0.05% Change
More quotes
Financials (USD)
Sales 2020 120 M - -
Net income 2020 -262 M - -
Net cash position 2020 544 M - -
P/E ratio 2020 -76,7x
Yield 2020 -
Sales 2021 306 M - -
Net income 2021 -157 M - -
Net cash position 2021 429 M - -
P/E ratio 2021 -153x
Yield 2021 -
Capitalization 20 315 M 20 315 M -
EV / Sales 2020 164x
EV / Sales 2021 65,0x
Nbr of Employees -
Free-Float 97,6%
More Financials
Company
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product... 
More about the company
Notations Surperformance© of Immunomedics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about IMMUNOMEDICS, INC.
10/15GILEAD SCIENCES : Announces Expiration of Hart-Scott-Rodino Waiting Period for I..
AQ
10/12IMMUNOMEDICS : Announces FDA Orphan Drug Designation of Trodelvyᵀᴹ f..
PU
10/12IMMUNOMEDICS : Announces FDA Orphan Drug Designation of Trodelvy™ for Adul..
AQ
10/12Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adu..
GL
09/25WEISSLAW LLP : Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing Investi..
PR
09/25WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Inve..
PR
09/24GILEAD SCIENCES : Prices $7.25 Billion of Senior Unsecured Notes
AQ
09/21IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/20(IMMU) ALERT : Johnson Fistel Investigates Proposed Sale of Immunomedics; Is $88..
PR
09/19IMMUNOMEDICS : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study..
PU
09/19IMMUNOMEDICS : Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ..
PU
09/19IMMUNOMEDICS : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study..
AQ
09/19Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Stud..
GL
09/19IMMUNOMEDICS : Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT ..
AQ
09/19Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Met..
GL
More news
News in other languages on IMMUNOMEDICS, INC.
09/14Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
09/14Wall Street profite du rebond de la tech
09/14Bourse Zurich: petite progression en entame de semaine
09/14WALL STREET STOCK EXCHANGE : L'Europe finit dans le désordre malgré la hausse de..
09/14Wall Street débute en hausse, la tech tente un rebond
More news
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 78,83 $
Last Close Price 87,82 $
Spread / Highest target 0,20%
Spread / Average Target -10,2%
Spread / Lowest Target -45,8%
EPS Revisions
Managers
NameTitle
Behzad Aghazadeh Executive Chairman
Usama Malik Chief Financial & Business Officer
Loretta M. Itri Chief Medical Officer
Peter Barton Hutt Independent Director
Scott A. Canute Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.315.03%20 291
LONZA GROUP AG64.78%47 655
SEAGEN INC.73.31%34 455
IQVIA HOLDINGS INC.12.29%33 260
CELLTRION, INC.34.81%28 816
MODERNA, INC.264.57%28 138